NCT02456675View on ClinicalTrials.gov

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 16, 2016

Study Completion Date

December 16, 2016

Conditions
Refractory Hodgkin LymphomaRecurrent Adult Hodgkin's Lymphoma
Interventions
DRUG

INCB040093 Monotherapy

INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.

DRUG

INCB040093

INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.

DRUG

itacitinib

The dose of itacitinib will be given orally once daily (QD).

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY